News tagged with median progression-free survival

Doxorubicin + trabectedin tied to increased survival in metastatic leiomyosarcoma

For patients with metastatic or surgically unresectable leiomyosarcoma, combination therapy with doxorubicin and trabectedin is associated with improved overall and progression-free survival compared with doxorubicin alone, ...